Fenwick Represents NEA in Leading Qpex Biopharma’s $33 Million Series A Financing

Fenwick & West represented New Enterprise Associates (NEA), one of the world’s largest and most active venture capital firms, in leading a $33 million Series A financing in Qpex Biopharma, a developer of a pipeline of agents addressing critical needs for the treatment of infectious diseases in the inpatient and outpatient settings. Others investors included Adams Street Partners, LYZZ Capital, Hatteras Venture Partners and Stanford University Draper Fund. Additional funding is being provided through an agreement with the Biomedical Advanced Research and Development Authority (BARDA).

The financing occurred in conjunction with the launch of the infectious disease company that will focus on developing new antibiotics to combat the growing threat of global antimicrobial resistance. Qpex, through its wholly-owned subsidiary, will continue its strategic partnership with BARDA with the potential for up to $132 million in support to develop a portfolio of new antibiotics. More information regarding NEA’s leading a $33 million financing in Qpex can be obtained from the company announcement.

The Fenwick transaction team was led by corporate lawyers Michael Brown, Lara Foster, Shiva Hippely and Elliot Ginsburg; technology transactions lawyers Stefano Quintini and Spencer Glende; and patent lawyers Dan Becker and Amy Hayden.